Dose Escalation Study of AST-OPC1 in Spinal Cord Injury

Phase 1

Completed

• Conditions: Cervical Spinal Cord Injury; Spinal Cord Trauma; Spine Injury
• Interventions: Biological: AST-OPC1

• Registration Number: NCT02302157
• Lead Sponsor: Lineage Cell Therapeutics, Inc.

Brief Summary

The purpose of this study is to evaluate the safety of cross sequential escalating doses of AST-OPC1 administered among 5 cohorts at a single time-point between 21 and 42 days post injury, inclusively, to subjects with subacute cervical spinal cord injuries (SCI).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2014-11-24
• Study First Submitted QC: 2014-11-25
• Study First Posted: 2014-11-26
• Study Start: 2015-03
• Primary Completion: 2018-12
• Study Completion: 2018-12
• Disposition First Submitted: 2020-07-14
• Disposition First Submitted QC: 2020-07-14
• Disposition First Posted: 2020-07-17
• Results First Submitted: 2020-12-15
• Status Verified: 2021-06
• Results First Submitted QC: 2021-06-21
• Last Update Submitted: 2021-07-12
• Results First Posted: 2021-07-13
• Last Update Posted: 2021-07-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

• Sensorimotor complete, traumatic SCI (ASIA Impairment Scale A) for cohorts 1,2,3
• Sensorimotor incomplete, traumatic SCI (ASIA Impairment Scale B) for cohorts 4,5
• Last fully preserved single neurological level (SNL) from C-4 to C-7
• From 18 through 69 years of age at time of injury
• Single spinal cord lesion on a post-stabilization magnetic resonance imaging (MRI) scan, with sufficient visualization of the spinal cord injury epicenter and lesion margins to enable post-injection safety monitoring
• Informed consent for this protocol and the companion long term follow-up protocol must be provided and documented (i.e., signed informed consent forms) no later than 37 days following injury
• Able to participate in an elective surgical procedure to inject AST-OPC1 21-42 days following SCI

Major

Read More

Exclusion Criteria

• SCI due to penetrating trauma
• Traumatic anatomical transection or laceration of the spinal cord based on prior surgery or MRI
• Any concomitant injury that interferes with the performance, interpretation or validity of neurological examinations
• Inability to communicate effectively with neurological examiner such that the validity of patient data could be compromised
• Significant organ damage or systemic disease that would create an unacceptable risk for surgery or immunosuppression
• History of any malignancy (except non-melanoma skin cancers)
• Pregnant or nursing women
• Body mass index (BMI) > 35 or weight > 300 lbs.
• Active participation in another experimental procedure/intervention

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
AST-OPC1	AST-OPC1	Open label, dose escalation, cross-sequential cohort of subjects who receive an injection or two injections of AST-OPC1 at a single time-point

Primary Outcome Measures

Name	Time	Method
Number of Adverse Events Within 1 Year (365 Days) That Are Related to AST-OPC1 Injection	One Year	Numbers of adverse events within 1 year (365 days) that are related to AST-OPC1 injection

Secondary Outcome Measures

Name	Time	Method
Neurological Function as Measured by Upper Extremity Motor Scores and Motor Level on International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) Examinations as Secondary End Point - 365 Days After Injection of AST-OPC1	One Year	The scale is based on the ISNCSCI (International Standards for Neurological Classification of Spinal Cord Injury) that measures the severity of Spinal cord injury. The data was collected per time point during the first year (30,60,90,180,270,365). The 365-days time point was pre-specified as Secondary Outcome Measure. High score means better outcome. Units are "Scores on a scale".; The score is divided to motor scale (0-100) and sensor scale (0-224).; Motor scale is divided to subscale of upper extremity (0-50) and lower extremity (0-50).; Upper and lower extremity are divided to subscale of Right (0-25) + Left (0-25).; Each upper \& lower extremity is divided to subscale of 5 motor nerve function (0-5).; Sensor scale is divided to subscale of light touch (0-112) and pin prick (0-112).; light touch and pin prick are divided to subscales of Right (0-56) + Left (0-56).; Each right and left light touch and pin prick are divided to subscales of 28 sensor nerve function (0-2)

Trial Locations

Locations (9)

Univ. of California at San Diego; 🇺🇸 La Jolla, California, United States

Rancho Los Amigos/USC; 🇺🇸 Los Angeles, California, United States

Shepherd Center; 🇺🇸 Atlanta, Georgia, United States

Washington University; 🇺🇸 Saint Louis, Missouri, United States

Stanford University/Santa Clara Valley Medical Center; 🇺🇸 San Jose, California, United States

Rush University Medical Center; 🇺🇸 Chicago, Illinois, United States

Indiana University; 🇺🇸 Indianapolis, Indiana, United States

Thomas Jefferson University/Magee Rehabilitation; 🇺🇸 Philadelphia, Pennsylvania, United States

Medical College of Wisconsin; 🇺🇸 Milwaukee, Wisconsin, United States